Newsfeed

Actionaria show : 2nd day at the Palais des Congrès in Paris

The doors open at 10:30 AM. Come and listen to our pitch by 11 AM and by 3 PM, and join us at the Medicen booth.

Big Booster Season #3 : Op2Lysis passed the first step in the selection process

The first step for selection in Big Booster, the international non-profit acceleration program for startups, which is organized across the globe over 4 continents, was held in Lyon. This was a 3-day session during which 100 startups shared their strategy, business plan and innovation. Following the pitch session that occured on Friday 17 October, Op2Lysis was selected to compete further in the Biotech & Health category.

More about Bigbooster : http://www.bigbooster.org/
The Op2Lysis executive summary which was submitted to Bigbooster: http://www.bigbooster.org/pdf/projects/Executive_Summary_OPLYSIS%20SAS.pdf
In the press : http://www.brefeco.com/actualite/innovation/big-booster-3-40-start-passent-la-premiere-etape

Op2Lysis patent granted in Japan

An additional step was achieved on last October, with Japan granting the patent that protects O2L-001. After US, this is the second large geographic area of patent protection. This decision strengthens our development and our international strategy.

http://www.theraprot.fr/op2lysis/wp-content/uploads/2017/11/Op2Lysis-new-thrombolytic-agents-patent-to-be-granted-in-Japan-VF.pdf

Op2Lysis is in Ouest-France

As a follow-up of our settlement with a new company settlement in Caen, Op2Lysis communicates in Ouest-France.

The article is available at the following address
https://www.ouest-france.fr/normandie/caen-14000/caen-une-start-travaille-sur-l-accident-vasculaire-cerebral-5363174

NETVA 2017 – A week of immersion / networking in Boston

One week of immersion in Boston, thanks to the NETVA program, coordinated by the Consulat de France in Boston, allowed us to benefit from the consulate network, as they introduced us into the biggested US ecosystem for Biotechs, including VCs, the local teams of Business France and of the French Tech Hub, preclinical CROs, and lawyers. We also met with renowned neurologists, emergency room physicians and neurosurgeons, as well as with neuroimaging specialists from Boston’s main hospitals (MGH, BU Hospital, Beth Israel). These early academic feedbacks were very encouraging on the potential of the therapeutic option that we develop.

More information about stroke and first care is needed

This is the conclusion of a survey led by the French stroke foundation on 986 people in October 2017. The questionnaire, which is available on the web, shows that one out of three people do not dial the emergency telephone number when facingstroke symptoms.

As a reminder, STROKE requires FAST action

(http://www.stroke.org/understand-stroke/recognizing-stroke/act-fast)

Sunday, 29 October – World Stroke Day

Question : Do you know about your blood pressure ?

90 % of the stroke events are related to ten modifiable risk factors. Prof. Serge Timsit, Neurologist and President of the « Société Française Neuro-Vasculaire (SFNV) » reports below.

http://www.francetvinfo.fr/sante/drogue-addictions/lutte-contre-le-tabagisme/avc-90-des-accidents-vasculaires-cerebraux-dependent-de-dix-facteurs-de-risque-modifiables_2441293.html

Op2Lysis US patent granted

The patent covering Op2Lysis’ O2L-001 innovation for the treatment of patients with a hemorrhagic stroke has been granted in the United States of America by the USPTO in July 2017.

A specific press release is available below

–> Click here  <–

R&D site opening in Caen

We are proud to announce the grand opening of our R&D site in Caen, at the Cyceron Center, where the Op2Lysis technology was invented. We also took the opportunity to show the laboratory to Estelle Louet, our first employee, who should join the team by December 2017 to work with us while pursuing her doctoral studies for a PhD level.

kick off of the Op2Lysis Crowdfunding campaign on WiSEED – Fundraising #1

As a result of a long and hard work, which was led over these last months and allowed a revision of the terms negotiated for the O2L-001 license, as well as gaining non-dilutive fundings (i-LAB and loans on trust) and numerous prizes and recognitions, Op2Lysis initiated its crowdfunding campaign on the WiSEED.com platform.

The objective of this fundraising is to fund the feasibility of the industrial production and formulation of O2L-001 over the next 12 months. At the end of this first period of our development program, we will have sufficient information on production, purification, and formulation to initiate the regulatory preclinical steps of O2L-001 development, with a compound able to liquefy an intracerebral hematoma with one single injection. Scale-up and preparation of the regulatory studies will require a second fundraising for 2019.